van Nuenen et al., 2005 - Google Patents
The effect of anti-TNF-α antibody therapy in Crohn's disease on composition and activity of faecal microbiota: a pilot studyvan Nuenen et al., 2005
View PDF- Document ID
- 13688616680683703106
- Author
- van Nuenen M
- van der Woude J
- Venema K
- Welling G
- Harmsen H
- van der Schaaf S
- Kuipers E
- Publication year
- Publication venue
- Composition and Activity of Gut Microbiota in Inflammatory Bowel Disease
External Links
Snippet
We aimed to determine whether anti-TNF-α monoclonal antibody therapy for Crohn's disease (CD) has an effect on the composition of the faecal microbiota in these patients. It was hypothesized that if the microbial composition correlates with clinical disease activity …
- 241000736262 Microbiota 0 title abstract description 84
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Micro-organisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving micro-organisms or compositions thereof; Processes of preparing or isolating a composition containing a micro-organism; Culture media therefor
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210106629A1 (en) | Compositions and Methods for Treating Inflammatory Bowel Diseases (IBDs) and Other Disorders | |
EP3468573B1 (en) | Treatment of clostridium difficile infection | |
Malo et al. | Intestinal alkaline phosphatase promotes gut bacterial growth by reducing the concentration of luminal nucleotide triphosphates | |
JP6954563B2 (en) | Use of pasteurized Akkermansia to treat metabolic disorders | |
CN113293113B (en) | Bifidobacterium longum MI-186 and application thereof | |
US20220313754A1 (en) | Bifidobacterium lactis bl-99 and application thereof | |
CA2810698A1 (en) | Aryl hydrocarbon receptor-activating probiotics for preventing inflammation | |
US11833178B2 (en) | Bifidobacterium longum for treating obesity and weight management | |
CN113234640A (en) | Bifidobacterium longum MF-269 and application thereof | |
JP2022547330A (en) | Compositions and methods for treating autism spectrum disorders | |
Teng et al. | An early fecal microbiota transfer improves the intestinal conditions on microflora and immunoglobulin and antimicrobial peptides in piglets | |
US20200164000A1 (en) | Compositions and methods for treating disorders related to a gut dysbiosis | |
WO2021097288A1 (en) | Compositions and methods for treating neurodegenerative diseases | |
CN113337440A (en) | Lactobacillus salivarius MG-587 and application thereof | |
JP2006180836A (en) | Lactic acid bacterium controlling infection with food poisoning bacterium, fermentation product, food and medicine composition containing the same | |
JP2021526526A (en) | Composition containing a bacterial strain | |
EP4306118A1 (en) | Composition and ameliorating agent having inflammation reducing effect | |
van Nuenen et al. | The effect of anti-TNF-α antibody therapy in Crohn’s disease on composition and activity of faecal microbiota: a pilot study | |
EP4384206A1 (en) | Aldehyde dehydrogenase producing bacteria and methods of using same | |
AU2022341608A1 (en) | Use of bacillus amyloliquefaciens for preventing and treating parkinson's disease | |
CN111132684A (en) | Twin blood cocci as biotherapeutic agents | |
JP2019045353A (en) | Method for detecting change of intestinal bacterial flora by using aquapolin as index | |
TW202140049A (en) | Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv) | |
Gancarčíková et al. | Antibiotic-treated SPF mice as a gnotobiotic model | |
Nikolić | Diabetes mellitus and obesity as a result of a disrupted homeostatic microbiome. New data on etiopathogenesis of diabetes mellitus |